What Ozempic Is Used For: Approved Indications by Category

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This page is part of the PlexusDx Education Hub, our library on GLP-1 therapies and the genetics behind metabolic decisions. Browse all Peptides & GLP-1 education.

"What is Ozempic used for" is best answered by category, because the semaglutide molecule and its class cousins carry several distinct approved uses. This page walks through those indications one at a time, then steps back to the shared mechanism, the cautions, and the upstream genetics — a structure meant to make the approved landscape easy to navigate as of April 2026.

Type 2 diabetes

The most widespread indication across the class is type 2 diabetes, which most compounds hold. Ozempic itself is Novo Nordisk's semaglutide brand, and semaglutide is FDA-approved for type 2 diabetes as Ozempic and, in oral form, as Rybelsus. All these products contain the same active ingredient but carry separate FDA labels and separate insurance-coverage logic.

Chronic weight management

A second category is chronic weight management, held by products such as Wegovy, Saxenda, and Zepbound. Here the medications reduce caloric intake through mechanism-mediated changes in appetite and satiety, and dosing is titrated upward from a starting dose over several weeks per each product's label. Because coverage rules differ by indication, a weight-management prescription is treated differently from a diabetes one even when the molecule is identical.

Cardiovascular and sleep-apnea indications

Several products in the class also carry an indication for cardiovascular risk reduction in type 2 diabetes. And as of 2024, Zepbound is additionally approved for obstructive sleep apnea in adults with obesity. The pattern across all of these is consistent: prescribing matches the brand's FDA-approved indication, and the same molecule under a different brand is not automatically interchangeable for insurance or coverage purposes.

The shared mechanism behind the uses

Every one of those uses rests on the same core biology. GLP-1 receptor agonists and GIP/GLP-1 dual agonists act on appetite regulation, satiety signaling, and gastric emptying. Body-weight and glycemic effects depend on the compound, dose, adherence, and individual factors. The trial programs behind these indications — SURMOUNT and SURPASS, STEP and SUSTAIN, AWARD, and LEAD and LEADER — are published in The New England Journal of Medicine, The Lancet, and The Lancet Diabetes & Endocrinology.

Where the approved uses stop

GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal, most pronounced during dose escalation, and rare serious events include pancreatitis, gallbladder disease, and acute kidney injury in the context of dehydration.

The genetics upstream of every indication

No matter which approved use applies, your metabolic terrain is set upstream. Variants in FTO, GLP1R, MC4R, and TCF7L2 shape baseline GLP-1 signaling, appetite, and energy balance. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, providing pathway-level context that never predicts response to a specific compound. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols.

Why the indication, not the molecule, defines the use

A recurring source of confusion is the assumption that a single active ingredient means a single use. In this class the opposite is often true: the same molecule can carry different approved uses under different brand names, each tied to its own trials and labeling. That is why a product approved for diabetes and a product approved for weight management can share a chemical identity yet be treated as separate options in the clinic and at the pharmacy.

For anyone mapping what a drug is used for, the practical takeaway is to look at the specific product and its label rather than the ingredient alone. The indication printed on a prescription is what a provider is treating and what a plan evaluates for coverage, so it, more than the molecule, defines the real-world use that applies to a given person. Reading a product this way also clears up why two brands that share an ingredient can sit in different formulary tiers and answer to different prior-authorization rules.

Frequently Asked Questions

What is the most common approved use?

Type 2 diabetes is the most widespread indication across the class, held by most compounds, and semaglutide is FDA-approved for it as Ozempic and, in oral form, as Rybelsus. Weight management, cardiovascular risk reduction, and obstructive sleep apnea are additional approved uses held by specific products.

Can one brand be swapped for another with the same molecule?

Not automatically. Prescribing matches each brand's FDA-approved indication, and the same molecule under a different brand is not automatically interchangeable for insurance or coverage purposes. That is why the specific product and its label, not just the active ingredient, determine approved use and coverage.

Does a genetic test reveal what I should use it for?

No. The Precision Peptide Genetic Test does not predict response or determine indication. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology, giving upstream context that applies across every approved use in the class.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.